MedPath

NMPA Approvals

Chinese National Medical Products Administration approved drug approval numbers and registration information

National Medical Products Administration
China
166,322 Approvals
Showing 961 to 980 of 166,322 approvalsPage 49 of 8317

Eptazocine Hydrobromide Injection

Approval Number: 国药准字H20253797
Registration: Apr 1, 2025

Pregabalin Oral Solution

Approval Number: 国药准字H20253749
Registration: Apr 1, 2025

Dapagliflozin Tablets

Approval Number: 国药准字H20253767
Registration: Apr 1, 2025

Carbazochrome Sodium Sulfonate Injection

Approval Number: 国药准字H20258048
Registration: Mar 31, 2025

Valacyclovir Hydrochloride Tablets

Approval Number: 国药准字H20258047
Registration: Mar 28, 2025

Tadalafil Tablets

Approval Number: 国药准字H20258045
Registration: Mar 28, 2025

Tadalafil Tablets

Approval Number: 国药准字H20258046
Registration: Mar 28, 2025

Fudosteine Oral Solution

Approval Number: 国药准字H20253709
Registration: Mar 25, 2025

Thioctic Acid Tablets

Approval Number: 国药准字H20253713
Registration: Mar 25, 2025

Rivaroxaban Tablets

Approval Number: 国药准字H20258041
Registration: Mar 25, 2025

Olanzapine Tablets

Approval Number: 国药准字H20253703
Registration: Mar 25, 2025

Omeprazole and Sodium Bicarbonate Capsules(Ⅱ)

Approval Number: 国药准字H20253726
Registration: Mar 25, 2025

Levetiracetam Sustained-release Tablets

Approval Number: 国药准字H20253711
Registration: Mar 25, 2025

Aminophylline Injection

Approval Number: 国药准字H20253717
Registration: Mar 25, 2025

Arbidol Hydrochloride Tablets

Approval Number: 国药准字H20253696
Registration: Mar 25, 2025

Neostigmine Methylsulfate Injection

Approval Number: 国药准字H20253700
Registration: Mar 25, 2025

Risperidone Tablets

Approval Number: 国药准字H20253707
Registration: Mar 25, 2025

Sodium Hyaluronate Eye Drops

Approval Number: 国药准字H20253740
Registration: Mar 25, 2025

Norepinephrine Bitartrate Injection

Approval Number: 国药准字H20258042
Registration: Mar 25, 2025

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Product

Company

Legal

© 2025 MedPath, Inc. All rights reserved.